glp-1-directed nmda receptor antagonism for obesity treatment Nature：重大进展！利用减肥激素GLP-1递送阻断NMDA受体的小分子到大脑中，可显著达到减肥效果- 生物研究专区- 生物谷 A metabolic balance of GLP-1

Injections like BPC-157, TB-500, and GHK-Cu are being pushed as "revolutionary, life-changing" miracles for chronic pain, tissue repair, and hypermobile Ehlers-Danlos Syndrome (hEDS)

We found that among patients with diabetes aged 66 and older, the incidence of nAMD was approximately 1 in 1,000 in those who had never used GLP-1 receptor agonists, compared to about 2 in 1,000 among those who had been exposed to these medications for at least six months, Muni said

SGLT2 Inhibitors and Cardioprotection: A Matter of Debate and Multiple Hypotheses

The pharmacokinetic profiles of tirzepatide and beta blockers suggest minimal direct drug-drug interactions

An injectable form is considered far more effective than topical, as it works systemically and bypasses the top layer of the skin

Human half-life unknown